The effects of recombinant human growth hormone (rhGH) on the serum levels of cytokines in severely burned patients.
- Author:
Zhigang LIANG
1
;
Xilin LIU
;
Jiang LI
;
Lizhen HUO
;
Darong LIANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Burns; blood; complications; drug therapy; Cytokines; blood; drug effects; Dose-Response Relationship, Drug; Female; Human Growth Hormone; pharmacology; therapeutic use; Humans; Interleukin-6; blood; Interleukin-8; blood; Lipopolysaccharides; blood; Male; Middle Aged; Multiple Organ Failure; etiology; mortality; Recombinant Proteins; pharmacology; therapeutic use; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; metabolism
- From: Chinese Journal of Burns 2002;18(1):49-51
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effects of recombinant human growth hormone (rhGH) on the serum levels of cytokines in severely burned patients.
METHODSThirty-six burn patients were enrolled in the study and were randomly divided into 3 groups according to the rhGH dosage used, i.e. small (0.3 IU.kg(-1).d(-1), A), large (0.6 IU.kg(-1).d(-1), B) dose groups and control group (C, with normal saline). The rhGH was administered beginning from 3 postburn days (PBDs) and lasted for 20 days. The dynamic changes in the serum levels of TNFalpha, IL-6, IL-8 and LPS at different time points were observed.
RESULTSWhen compared with those in C group, the serum levels of TNFalpha, IL-6 in A, B groups were decreased, especially in B group with earlier decrease and bigger range (P < 0.01). Simultaneously, the serum LPS level was decreased accordingly with evident positive correlation with the change in those cytokines (r = 0.9723, P < 0.01). But there was no obvious difference in serum IL-8 level among A, B and C groups (P > 0.05).
CONCLUSIONrhGH might decrease the production of postburn inflammatory mediators, especially in higher dose in dose-dependent manner for some degree. The clinical application of rhGH might be a supplementary measure in preventing and ameliorating postburn SIRS and MODS in severely burned patients.
